Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Public ClinicalTrials.gov record NCT07750158. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Study identification
- NCT ID
- NCT07750158
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Interventions
- Zanzalintinib Drug
- Pembrolizumab (+) Berahyaluronidase alfa Biological
- Placebo Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2026
- Primary completion
- Apr 4, 2030
- Completion
- Apr 4, 2030
- Last update posted
- Sep 20, 2026
2026 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 3
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs | Council Bluffs | Iowa | 51503 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island | Grand Island | Nebraska | 68803 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional | Grand Island | Nebraska | 68803 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist | Omaha | Nebraska | 68114 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan | Omaha | Nebraska | 68124 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy | Omaha | Nebraska | 68130 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Papillion | Papillion | Nebraska | 68046 | Recruiting |
| Astera Cancer Care | Bridgewater | New Jersey | 08807 | Recruiting |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | Recruiting |
| Astera Cancer Care | Edison | New Jersey | 08820 | Recruiting |
| Astera Cancer Care | Monroe | New Jersey | 08831 | Recruiting |
| Astera Cancer Care | Somerset | New Jersey | 08873 | Recruiting |
| Astera Cancer Care | Toms River | New Jersey | 08757 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07750158, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2026 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07750158 live on ClinicalTrials.gov.